Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors. These drugs prevent the growth of malignant tumors by affecting the process of cell division or by damaging the DNA and initiate apoptosis or by preventing the development and spread of neoplastic cells. Several types of cancers that can be treated by oncology drugs are blood cancer, lung cancer, endocrine cancer, bone cancer, gastric cancer, colorectal cancer, skin cancer, breast cancer, pancreatic cancer, prostate cancers, ovarian cancer, ocular cancer and others.
The global oncology drugs market was valued around $126 billion in 2017. North America was the largest region in the oncology drugs market in 2017, accounting for around 30% of the total market. The USA was the largest country in the market accounting for around 25% of the total market.
Companies in the oncology drug market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive oncology drug market, companies are developing innovative products as well as sharing skills and expertise with other companies.
The top five companies covered are F. Hoffmann-La Roche Ltd., Novartis AG, Gilead Sciences, Inc., Bayer AG and Takeda Pharmaceuticals. F. Hoffmann-La Roche Ltd. was the largest company in the oncology drugs market.
The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.
The oncology drugs market in this report is segmented into oncology drugs, drugs for blood cancer, breast cancer, cervical cancer, lung cancer, prostate cancer, kidney cancer, colorectal cancer, thyroid cancer, non-small cell lung cancer, gastric cancer, brain tumor, pancreatic cancer, skin cancer, ovarian cancer, bladder cancer and others.
Blood cancer share attributes to large population of cancer patients suffering from various types of blood cancers such as Leukemia, Lymphoma, and Myeloma.
Breast cancer increases in aging population, improvement in the survival rates with early diagnosis, access to medical care and progressive improvement in treatment strategies contribute to the market share.
Cervical cancer contributing to the size of this market include increase in aging population, improved diagnosis for cervical cancer leading to more patients being exposed to treatment.
Lung cancer increases the demand for therapeutics which has contributed to the size of this market.